Global Influenza diagnostics Market to reach USD 3.6 billion by 2025.

---

---

Global Influenza diagnostics Market valued approximately USD 1.91 billion in 2016 is anticipated to grow with a healthy growth rate of more than 6.4% over the forecast period 2020-2027. Influenza, which is commonly called the flu is an infectious disease of the upper respiratory system caused by the influenza virus. The seasonal influenza virus has three types, namely influenza B, influenza A, and influenza C that are differentiated on the basis of two major surface proteins namely, hemagglutinin (HA) and neuraminidase (NA). Various serotypes are seen based on differences in these surface proteins that determine the antibody response to the viruses.

---

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

---

---

By Test type:

---

---

 RIDT

---

 RT-PCR

---

 Cell culture

---

---

By End Use:

---

---

 Hospitals

---

 Laboratories

---

 POCT

---

---

---

By Regions:

---

 North America

---

o U.S.

---

o Canada

---

 Europe

---

o UK

---

o Germany

---

 Asia Pacific

---

o China

---

o India

---

o Japan

---

 Latin America

---

o Brazil

---

o Mexico

---

 Rest of the World

---

---

Furthermore, years considered for the study are as follows:

---

---

Historical year – 2016 to 2018

---

Base year – 2019

---

Forecast period – 2020-2027

---

---

Some of the key manufacturers involved in the market 3AM Healthcare, Alere, meridian bioscience, Inc., Quidel corporation, Roche diagnostics corporation, SA Scientific, Thermo fisher scientific Inc. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

---

---

Target Audience of the Global Influenza diagnostics Market in Market Study:

---

---

 Key Consulting Companies & Advisors

---

 Large, medium-sized, and small enterprises

---

 Venture capitalists

---

 Value-Added Resellers (VARs)

---

 Third-party knowledge providers

---

 Investment bankers

---

 Investors

---

---

FIG 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET, KEY TRENDS 2016
FIG 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET, GROWTH PROSPECTS 2020-2027
FIG 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET, PEST ANALYSIS
FIG 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 16. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 17. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 18. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 19. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 20. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 21. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 23. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 24. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 25. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 26. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 27. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 28. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 29. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 30. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY SEGMENT, 2016-2027 (USD BILLION)
FIG 31. GLOBAL INFLUENZA DIAGNOSTICS MARKET, REGIONAL SNAPSHOT 2016-2027
FIG 32. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET 2016-2027 (USD BILLON)
FIG 33. EUROPE INFLUENZA DIAGNOSTICS MARKET 2016-2027 (USD BILLON)
FIG 34. ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET 2016-2027 (USD BILLON)
FIG 35. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET 2016-2027 (USD BILLON)
FIG 36. GLOBAL INFLUENZA DIAGNOSTICS MARKET, COMPANY MARKET SHARE ANALYSIS (2016)

Chapter 1. Global Influenza diagnostics Market Definition and Scope
1.1. Research Objective
1.2. Market Definition
1.3. Scope of The Study
1.4. Years Considered for The Study
1.5. Currency Conversion Rates
1.6. Report Limitation
Chapter 2. Research Methodology
2.1. Research Process
2.1.1. Data Mining
2.1.2. Analysis
2.1.3. Market Estimation
2.1.4. Validation
2.1.5. Publishing
2.2. Research Assumption
Chapter 3. Executive Summary
3.1. Global & Segmental Market Estimates & Forecasts, 2016-2027 (USD Billion)
3.2. Key Trends
Chapter 4. Global Influenza diagnostics Market Dynamics
4.1. Growth Prospects
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Industry Analysis
4.2.1. Porter’s 5 Force Model
4.2.2. PEST Analysis
4.2.3. Value Chain Analysis
4.3. Analyst Recommendation & Conclusion
Chapter 5. Global Influenza diagnostics Market, By Test type
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Global Influenza diagnostics Market, Sub Segment Analysis
5.3.1. RIDT
5.3.1.1. Market estimates & forecasts, 2016-2027 (USD Billion)
5.3.1.2. Regional breakdown estimates & forecasts, 2016-2027 (USD Billion)
5.3.2. RT-PCR
5.3.2.1. Market estimates & forecasts, 2016-2027 (USD Billion)
5.3.2.2. Regional breakdown estimates & forecasts, 2016-2027 (USD Billion)
5.3.3. Cell culture
5.3.3.1. Market estimates & forecasts, 2016-2027 (USD Billion)
5.3.3.2. Regional breakdown estimates & forecasts, 2016-2027 (USD Billion)

Chapter 6. Global Influenza diagnostics Market, By End Use
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Global Influenza diagnostics Market, Sub Segment Analysis
6.3.1. Hospitals
6.3.1.1. Market estimates & forecasts, 2016-2027 (USD Billion)
6.3.1.2. Regional breakdown estimates & forecasts, 2016-2027 (USD Billion)
6.3.2. Laboratories
6.3.2.1. Market estimates & forecasts, 2016-2027 (USD Billion)
6.3.2.2. Regional breakdown estimates & forecasts, 2016-2027 (USD Billion)
6.3.3. POCT
6.3.3.1. Market estimates & forecasts, 2016-2027 (USD Billion)
6.3.3.2. Regional breakdown estimates & forecasts, 2016-2027 (USD Billion)


Chapter 7. Global Influenza diagnostics Market, by Regional Analysis
7.1. Influenza diagnostics Market, Regional Market Snapshot (2016-2027)
7.2. North America Influenza diagnostics Market Snapshot
7.2.1. U.S.
7.2.1.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.2.1.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.2.1.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.2.2. Canada
7.2.2.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.2.2.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.2.2.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3. Europe Influenza diagnostics Market Snapshot
7.3.1. U.K.
7.3.1.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.3.1.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3.1.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3.2. Germany
7.3.2.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.3.2.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3.2.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3.3. France
7.3.3.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.3.3.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3.3.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3.4. Rest of Europe
7.3.4.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.3.4.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.3.4.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4. Asia Influenza diagnostics Market Snapshot
7.4.1. China
7.4.1.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.4.1.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4.1.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4.2. India
7.4.2.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.4.2.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4.2.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4.3. Japan
7.4.3.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.4.3.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4.3.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4.4. Rest of Asia Pacific
7.4.4.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.4.4.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.4.4.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.5. Latin America Influenza diagnostics Market Snapshot
7.5.1. Brazil
7.5.1.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.5.1.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.5.1.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.5.2. Mexico
7.5.2.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.5.2.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.5.2.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.6. Rest of The World
7.6.1. South America
7.6.1.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.6.1.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.6.1.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.6.2. Middle East and Africa
7.6.2.1. Market estimates & forecasts, 2016-2027 (USD Billion)
7.6.2.2. Test type breakdown estimates & forecasts, 2016-2027 (USD Billion)
7.6.2.3. End Use breakdown estimates & forecasts, 2016-2027 (USD Billion)

Chapter 8. Competitive Intelligence
8.1. Company Market Share (Subject to Data Availability)
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. 3AM healthcare
8.3.1.1. Overview
8.3.1.2. Financial (Subject to Data Availability)
8.3.1.3. Product Summary
8.3.1.4. Recent Developments
8.3.2. Alere
8.3.3. Meridian bioscience Inc.
8.3.4. Quidel corporation
8.3.5. Roche diagnostics corporation
8.3.6. SA Scientific
8.3.7. Thermo fisher scientific Inc.